There continue to be incremental advances in thoracolumbar spine surgery techniques in attempts to achieve more predictable outcomes, minimize risk of complications, speed recovery, and minimize the costs of these interventions. This paper reviews recent literature with regard to emerging techniques of interest in the surgical treatment of lumbar spinal stenosis, fusion fixation and graft material, degenerative lumbar spondylolisthesis, and thoracolumbar deformity and sacroiliac joint degeneration. There continue to be advances in minimal access options in these areas, although robust outcome data are heterogeneous in its support. The evidence in support of sacroiliac fusion appears to be growing more robust in the properly selected patient.
T
here continue to be incremental advances in thoracolumbar spine surgery techniques in order to achieve more predictable outcomes, minimize risk of complications, speed recovery, and minimize the costs of these interventions. This paper reviews recent literature (published in the last 36 months) with regard to emerging techniques of interest in the surgical treatment of lumbar spinal stenosis, fusion fixation and graft material, degenerative lumbar spondylolisthesis, and thoracolumbar deformity and sacroiliac (SI) joint degeneration.
LUMBAR DECOMPRESSION STRATEGIES
Interspinous process spacers (ISSs) remain a subject of some interest for surgeons with purported benefits of lesser surgical invasiveness than open decompression for patients (often elderly with substantial medical comorbidities) who have symptomatic lumbar spinal stenosis.
Recently, the results of a comparative noninferiority trial between 2 ISSs were published. Superion ISS (VertiFlex, San Clemente, California) was demonstrated as equivalent to X-stop in its Food and Drug Administration (FDA) trial at 2 years with 77% demonstrating >20-mm improvement in leg pain at 2-year follow-up, 1 although this was not likely clinically significant. 2 In a different treatment approach, The Coflex ISS (Paradigm Spine, New York, New York) has been the subject of an FDA trial in which all patients received laminectomy, onethird of whom received fusion and two-thirds received the Coflex device. 3 At 3-year follow-up of the FDA cohort, those receiving the ISS (Paradigm Spine) had a slightly higher rate of clinical success. Unfortunately, this study did not include an arm with laminectomy alone which may have documented what the added benefit of the ISS is. Other contemporary studies have sought to address this question. In one, ISS may represent higher risk for reoperation and higher total cost vs traditional open decompression. 4 In another, there seems to be no benefit to adding an ISS to open decompression. 5 Posterior lumbar decompression techniques have been developed to be less invasive and require less destruction of muscle attachments, leading to descriptions of bilateral decompression through unilateral laminotomywhether done through a tubular retractor and microscope 6 or through an endoscope. 7 Another technique involves splitting the spinous process to facilitate bilateral access from unilateral laminotomy and then repairing the spinous process to preserve multifidus muscle attachments. 8 Overdevest et al 9 performed a systematic review of these techniques compared to standard open bilateral laminectomy. They included 10 randomized controlled trials (RCTs) in their analysis and found that unilateral and bilateral laminotomy to perform bilateral decompression may offer lower risk of iatrogenic instability as compared to bilateral laminectomy. They also found that postoperative low back pain may be lower in bilateral laminotomy and split-spinous process decompression as compared to bilateral laminectomy, but the difference is not likely clinically meaningful. 
Fusion Techniques
Surgeons continue to seek alternative methods and materials to iliac crest autograft to achieve fusion in select patients. In 2013, Khashan et al 10 performed a systematic review and found insufficient evidence to support the use of mesenchymal stem cells or bone marrow aspirate combined with synthetic or allograft material as a substitute for autologous bone graft. More recently, a small level-IV study cohort demonstrated satisfactory interbody fusion rates in patients over 65 using bone marrow aspirate concentrate with allograft and demineralized bone matrix.
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While this may show promise, clearly more evidence is needed for guidance on its use. The use of recombinant human bone morphogenic protein-2 (BMP-2) continues to evolve. In North America, BMP-2 use (much of it off-label from the US FDA perspective) tapered off after the FDA 2008 public health notification on its use in the cervical spine and then the focus edition in the Spine Journal in 2012. 12 The spectrum of complications associated with BMP-2 use in the spine continues to be clarified. 13 In addition to posterolateral intertransverse fusion and anterior lumbar interbody fusion, minimally invasive methods, including transforaminal lumbar interbody fusion, extraforaminal lumbar interbody fusion, lateral transpsoas interbody fusion, and oblique lumbar interbody fusion, have gained some popularity. Minimally invasive options appear to offer lower blood loss and infection risk at the cost of higher radiation exposure for the surgical team. 14, 15 Long-term comparison to open techniques demonstrating solid fusion and adequate decompression has yet to convincingly address these questions. The complication profiles appear to differ for each of these approaches, with durotomy 16 for transforaminal lumbar interbody fusion, radiculopathy for extraforaminal lumbar interbody fusion, 17 psoas, lumbar plexus, or bowel injury with lateral transpsoas interbody fusion, 18 endplate fracture/subsidence and psoas weakness/thigh numbness most common in oblique lumbar interbody fusion. 19 New radiculopathies and rare bleeding complications have been reported for each of these fusion approaches.
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Fixation Techniques
There is a growing body of evidence to assist surgeons in achieving rigid, durable fixation. Pedicle screws placed parallel to endplate in healthy bone and at least penetrated past the neurocentral junction give a substantial likelihood of success. 21 However, one may wish to angle pedicle screws up toward the endplate to enhance fixation in osteoporotic bone. 22 Percutaneous pedicle screws may generally be placed safely, usually using guidewire, although placement without guidewire has been described as safe. 23 Cortical screw trajectory has been described using a more medial-to-lateral and caudal-to-cephalad trajectory to take advantage of denser bone for fixation. 24 These may be useful for fixation at levels with pedicles too small for a coaxial pedicle screws. 25 Cement augmentation to enhance screw fixation in osteopenic bone continues to receive attention. These techniques may inject cement into a pilot hole before placing a solid pedicle screw, or may employ fenestrated screws through which cement may be injected. 26 Either method seems to substantially enhance initial screw fixation, 27 but there remains a dearth of large clinical series demonstrating its utility and risk profile in adult deformity patients. There is also interest in prophylactic cement augmentation of the upper instrumented vertebra (UIV) and/or the first cranial vertebra above a long fusion construct (UIV+1) to mitigate risk of proximal junctional failure. One recent retrospective series suggests that prophylactic cement augmentation of the UIV+1 may be associated with decreased incidence of proximal junctional failure, but clearly more robust studies are required before this can be uniformly recommended. 28 Rigid interspinous process fixation may be an alternative to pedicle fixation. 29 In this technique, the spinous processes can be fused while preserving the posterior musculature and avoiding the neural elements; potentially less technically demanding than pedicle screw placement. Lopez et al 30 performed a recent systematic review of the supporting evidence for this technology finding no level I or II evidence and flaws, highly biased level III clinical evidence to support their effectiveness. It appears that we should be wary of relying on these devices to achieve the stated purposes above.
Spinopelvic fixation remains an extremely important component when addressing thoracolumbar deformities as more aggressive corrections put more substantial demands on caudal construct fixation. The AxiaLif ™ L5-S1 interbody device (TranS1 Inc., Wilmington, North Carolina) may offer rigid fixation, but was associated with a substantial complication rate (46.3%) when performed in deformity cases.
31 S2-alar-iliac screws are becoming more popular as pelvic fixation as they are generally less prominent and easier to connect to rods than screws through the iliac crest. One study suggests that they may be more accurately placed using robotic guidance.
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Where Are We on Degenerative Spondylolisthesis?
Patients with degenerative spondylolisthesis have a pathoanatomy that can consist of intersegmental instability, central canal stenosis, and foraminal stenosis. Surgical management of lumbar spondylolisthesis can offer patients improvements in pain, disability, and quality of life; however, the role of spinal fusion remains hitherto uncertain. The purported goals of arthrodesis include preventing the disease-related glacial instability and acutely stabilizing approach-related iatrogenic instability. A number of recent trials have summarized the role of spinal surgery in general and spinal fusion specifically in the patient with spondylolisthesis.
The Spine Patients Outcomes Research Trial (SPORT) evaluated surgical vs nonoperative therapy for patients with degenerative spondylolisthesis and symptoms spanning at least 12 weeks. From the 304 randomized patients, there was significant crossover in both directions with 66% of surgically randomized and 54% of nonoperatively randomized patients undergoing surgery at 4-year follow-up. The as-treated analysis revealed clinical advantage of surgical intervention for Short Form-36 (SF-36) and Oswestry Disability Index (ODI), with a 4-year reoperation rate in the surgical cohort of 15%. Abdu and coworkers 33 performed a subgroup analysis to assess whether fusion method influenced surgical outcome. The vast majority of patients underwent arthrodesis (94%) divided between noninstrumented (21%) and instrumented (56%) posterior approaches, and 17% underwent circumferential fusion. At 4-year follow-up, they could show no advantages to any particular fusion technique. Overall trial benefits were also observed in subgroup analysis of the octogenarian population with no increase in complications or mortality-compared younger population. 34 Obesity leads to lesser clinical improvement and higher rates of infection and reoperation among surgical patients. 35 Durotomy at surgery was noted in 10.5% of patients with no apparent impact on the measured outcomes. 36 Further, the SPORT cohort of patients has also been compared with 955 patients from the National Surgical Quality Improvement Program database to assess the study's external validity. Golinvaux and coworkers 37 describe similar age, race, operative time, complication rates, and postoperative mortality between the cohorts, suggesting that the results are widely generalizable.
Having established the benefit of surgical intervention for degenerative spondylolisthesis, the next question of importance pertains to the need for arthrodesis. Guha and coworkers 38 have recently summarized how lumbar decompressive surgery can destabilize the spine, requiring secondary spinal fusion. Among 24 studies, including 2496 patients undergoing decompression only, the presence of preoperative spondylolisthesis increased the likelihood of needing secondary fusion procedure from 1.8% overall to 9.3% (relative risk of 5.2). Application of minimally invasive techniques seems to mitigate this risk, but does not completely eliminate it. Ghogawala and coworkers 39 have reported on the Spinal Laminectomy vs Instrumented Pedicle Screw trial that randomized patients with degenerative spondylolisthesis to either decompression or decompression and instrumented fusion. 39 The primary outcome was SF-36 physical component summary score, with greater improvement sustained over 4 years among those patients undergoing fusion than decompression alone. The reoperation rate was higher among patients undergoing decompression only (34%, for instability) compared with fusion (14%, for adjacent-segment disease). Similar improvements in disability measured by ODI were noted among both groups. In other work, Lad and coworkers 40 have used the MarketScan™ (Truven Health Analytics Inc., Ann Arbor, Michigan) to assess the difference between decompression with or without various forms of arthrodesis for spondylolisthesis. Assessing 16 556 patients over 2000 to 2009, they demonstrated that index hospitalization costs and associated complication rates during the index hospitalization and at 90-day followup were higher among the arthrodesis cohort than those receiving decompression alone. Conversely, the decompression-only cohort exhibited higher reoperation rates than those who underwent arthrodesis. It seems that including arthrodesis on the degenerative spondylolisthesis patient incurs higher index cost, but may decrease the need for potential reoperation.
SI Joint Degeneration
Annual US direct health care expenditures for chronic back pain may be as much as $90 billion dollars. 41 The SI joint was identified as potentially pain generating in 1900s, and it has been shown to be a source of pain in up to 40% of adults with chronic low back pain. [42] [43] [44] [45] Among patients who have previously undergone lumbar fusion, 75% of individuals will demonstrate radiographic evidence of SI degeneration 5 years after their index fusion 46 and ≥40% of postfusion patients with ongoing low back pain will be diagnosed with SI joint pain. 47, 48 SI joint pain has been shown to have a profound effect on patient disability and health-related quality of life. Compared to age-and gendermatched controls, adult patients with degenerative sacroiliitis or SI joint disruption have significantly worse outcomes on the SF-36 mental and physical component scores, Short Form-6D, and EuroQoL 5D (EQ-5D) 49 It would seem that effective therapies for degenerative SI joint pain have the possibility of significantly decreasing the burden of disease associated with this often overlooked diagnosis.
SI joint fusion for lower back pain was first introduced in the 1920s, 50 with original techniques involving open procedures. 51 Minimally invasive SI joint fusion was developed to overcome the high morbidity and complication rates associated with open surgery, and has been described through either a dorsal or lateral transarticular approach. Techniques for dorsal minimally invasive SI joint fusion include allograft fibula dowels, autograft iliac crest, and titanium cages with bone graft while lateral transarticular techniques include hollow screw-like implants with bone graft and regular screw fixation. 52 However, the most frequently studied technique involves percutaneous placement of multiple triangular titanium implants.
Three systematic reviews of the literature have examined the clinical effectiveness of SI joint fusion, 2 including both open and minimally invasive fusion 53, 54 and 1 focusing solely on (MIS). 55 Since the publication of these systematic reviews, several highquality prospective studies of minimally invasive SI joint fusion employing strict inclusion criteria have been published. Sixmonth outcomes of a European RCT of triangular titanium implants for minimally invasive SI joint fusion (iFuse Implant System, SI-BONE Inc., San Jose, California) vs conservative treatment demonstrate superior outcomes with regard to low back pain, ODI, EQ-5D, walking distance, and patient satisfaction with no difference in complication rates. 56 Twelvemonth results from the American Investigation of Sacroiliac Fusion Treatment RCT using the same implant found improved success rates (81.4% vs 26.1%; success defined as achieving reduction in VAS pain by at least 20 mm, no device-related serious adverse events, no neurological worsening due to nerve root impingement and no reoperation) following MIS SI fusion compared to nonoperative treatment with significantly greater rates of achieving a clinically important improvement in ODI scores (73.3% vs 13.6%). 57 Finally, 24-month results of a singlearm, prospective multicenter trial demonstrate durability of clinical improvements with significant decreases in VAS pain ratings (79.8-26.0), ODI scores (55.2-30.9), SF-36, and EQ-5D scores. 58 At 12-month follow-up, 97% of high-resolution CT scans performed on all patients showed bone adherence to 2 or 3 implants on both the iliac and sacral sides of the joint. Implantrelated adverse events reported in these 3 trials ranged from 1.0% to 4.1%.
In addition to the favorable clinical results of minimally invasive SI joint fusion, investigators have begun to examine the value of this treatment modality for SI joint disruption and degenerative sacroiliitis. To date, minimally invasive data suggest that MIS SI fusion is cost-effective with a cost-per-QALY of $13 313 USD. 49, 59 Further, it has been suggested that failure to include the SI joint in the diagnostic work-up and treatment plan for low back pain risks additional health care expenditures of $3100 USD per patient at 2 years. 60 As a result of increasing clinical data in support of minimally invasive SI joint fusion, coverage for the procedure has been endorsed by both the International Society for the Advancement of Spine Surgery 61 and the North American Spine Society.
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Annual rates of MIS techniques have increased 63, 64 with 87% of all SI joint fusions performed by polled surgeons utilizing a MIS approach. 65 However, despite these compelling results, several limitations to the current literature exist, including a lack of nonindustry-sponsored high-quality prospective studies with longer term follow-up, and questions regarding the durability of the implants and radiologically confirmed fusion rates have yet to be answered.
CONCLUSION
There continues to be substantial interest in minimizing surgical invasiveness when treating degenerative spinal conditions, and it seems that MIS techniques hold promise in decreasing infection risk for patients. It remains to be seen whether these techniques offer equally durable results as their more invasive predecessors. Poor bone health in the aging degenerative spine patient continues to substantially degrade fixation options, although augmentation techniques and new trajectories offer some promise. The spine surgery community continues to discern and refine the advisability of surgical undertakings in the elderly deformity patient, but it seems clear that the general health burden of spinal deformity is significant and likely to grow with our aging populations. With the growing prevalence of spine fusions in our population, it would be wise to appreciate the potential of SI joint degeneration as a subsequent source of pain, and the evidence supporting the effectiveness of SI fusion is growing more robust.
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